Clinical trials
Pulmonary Fibrosis clinical trials
Below are recruiting pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 143 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07332117Recruiting
Studying body changes in IPF and PPF patients starting anti-fibrotic drugs
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
LondonAges 18 years+ - NCT00373841Recruiting
Study of genetic and protein changes in idiopathic pulmonary fibrosis
This study looks at genetic (DNA) and protein changes over time in people with idiopathic pulmonary fibrosis, to better understand how the disease progresses. Your participation may help researchers learn patterns that could guide future care.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06488638Recruiting
Beetroot juice supplement for lung fibrosis
This trial tests whether a beetroot juice drink (rich in nitrates) can help people with idiopathic pulmonary fibrosis breathe better and exercise more. It's a small pilot study to see if it's safe and worth studying further.
SouthamptonAges 18–85 - NCT07464912RecruitingPhase 3
Testing TDI01 for idiopathic pulmonary fibrosis
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
Beijing, Beijing MunicipalityAges 40–80 - NCT07466420Recruiting
Quercetin for fibrotic lung disease
This trial tests whether taking quercetin, a natural supplement, can help people with fibrotic interstitial lung diseases (a group of conditions that cause scarring in the lungs). If you have been diagnosed with idiopathic pulmonary fibrosis (IPF) or another fibrotic ILD and are on standard treatments, you may be able to join.
Heraklion, CreteAges 18 years+ - NCT07486206Recruiting
Optimizing follow-up for interstitial lung disease
This trial tests a new way to organize follow-up visits for people with interstitial lung disease (a group of lung conditions). It aims to make care simpler and more effective for patients who are already on treatment.
Granollers, BarcelonaAges 18 years+ - NCT06940531Recruiting
Tracking causes of lung flare-ups in cystic fibrosis
This study aims to understand what causes and increases the risk of lung infections (exacerbations) in people with cystic fibrosis. It involves regular monitoring and sample collection at home and in the clinic to identify early warning signs.
Manchester, ManchesterAges 5 years+ - NCT07761377Recruiting
Using AI to spot lung scarring on CT scans
This study tests whether an AI tool can correctly find lung scarring (pulmonary fibrosis) on CT scans as well as doctors do. The results could lead to faster, more consistent detection of this condition.
TaichungAges 20 years+ - NCT06546943Recruiting
Glucose monitoring in youth with cystic fibrosis
This study uses a continuous glucose monitor (a small sensor on the arm) to track blood sugar levels in young people with cystic fibrosis during a lung infection flare-up (called a pulmonary exacerbation). It aims to see if glucose changes can help guide treatment.
Aurora, ColoradoAges 6–25 - NCT00001532Recruiting
How Genes Affect Lung Disease Development
This research study examines how genetic factors contribute to various lung diseases, including alpha-1 antitrypsin deficiency, cystic fibrosis, and chronic obstructive pulmonary disease. Researchers want to understand why some people develop lung disease and how genetics plays a role, which may help improve treatment in the future.
Bethesda, MarylandAges 2–90 - NCT05674994RecruitingPhase 3
Steroid versus placebo for sudden worsening of lung scarring
This Phase 3 trial studies whether glucocorticoid (steroid) medicine helps people with idiopathic pulmonary fibrosis (IPF) who have a sudden flare-up, compared with an inactive placebo. You may be helped if steroids improve breathing and recovery during these acute episodes, but the study is designed to test that clearly.
AngersAges 18 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Birmingham, AlabamaAges 40 years+ - NCT05943535RecruitingPhase 3
Breathing treprostinil to slow progressive lung scarring
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Birmingham, AlabamaAges 18 years+ - NCT06714123RecruitingPhase 2
Senicapoc for worsening lung scarring
This trial tests if the drug senicapoc can help people whose lung scarring (pulmonary fibrosis) is getting worse despite standard care. It aims to slow down the decline in lung function.
Aarhus NAges 18 years+ - NCT07269262Recruiting
Support program for PPF patients and their caregivers
This study tests a support program for people with progressive pulmonary fibrosis and their caregivers. It focuses on helping both the patient and the person who helps care for them.
Charleston, South CarolinaAges 18 years+ - NCT07312305Recruiting
Small airways test in idiopathic pulmonary fibrosis
This study measures how well the small airways in your lungs work if you have idiopathic pulmonary fibrosis (IPF). It aims to find better ways to assess the disease and could lead to improved care.
Milan, LombardyAges 18 years+ - NCT07683728Recruiting
Observational study of progressive pulmonary fibrosis (PPF) in China
This study is a registry that collects information from people in China who have progressive pulmonary fibrosis (PPF), a lung condition that gets worse over time. It aims to better understand the disease and help doctors improve care.
BeijingAges Any age - NCT05548283RecruitingPhase 4
Standard IV antibiotic timing for cystic fibrosis lung flare-ups
This study standardizes how IV aminoglycoside antibiotics are given during a 14-day treatment for cystic fibrosis (CF) lung flare-ups. It may help make treatment more consistent and easier to manage for people who need IV antibiotics.
Birmingham, AlabamaAges 6 years+ - NCT06527612Recruiting
Exercise's effect on lung disease and quality of life
This study looks at whether a personalized exercise program can improve quality of life and slow down lung disease in people with fibrosing interstitial lung disease. If you have trouble breathing when active and have been stable for the past month, you may be able to join.
Istanbul, ÜsküdarAges 18–75 - NCT05098717Recruiting
PEEP settings guided by lung pressure in pulmonary fibrosis
This trial tests whether using lung-pressure measurements to adjust ventilator PEEP (a breathing-support setting that keeps airways open) can help people with pulmonary fibrosis who are on a breathing machine for acute respiratory failure. It may improve breathing comfort and oxygenation by finding the best PEEP level for you.
ModenaAges 18–90 - NCT04965298RecruitingPhase 3
Lansoprazole add-on treatment for idiopathic pulmonary fibrosis
This Phase 3 study tests whether adding lansoprazole (a stomach acid medicine) can improve outcomes for people with idiopathic pulmonary fibrosis (IPF). You may already be on IPF “anti-fibrotic” medication, and the study checks if the added lansoprazole helps, compared with placebo.
Norwich, NorfolkAges 40 years+ - NCT06445686Recruiting
Monitoring Vital Signs in Idiopathic Pulmonary Fibrosis
This study monitors your vital signs before and after a sudden worsening (flare-up) of IPF. It uses a wearable device (Bora Band®) to track your health and help doctors better understand and manage these events.
RennesAges 18 years+ - NCT07036523RecruitingPhase 2
Study of BI 765423 for people with Idiopathic Pulmonary Fibrosis (IPF)
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
Birmingham, AlabamaAges 40 years+ - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Birmingham, AlabamaAges 21 years+
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pulmonary fibrosis?
- Yes. Clin2 currently lists 143 recruiting pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.